Severe Hypercholesterolemia:
Better Patient Outcomes Through Early Diagnosis and Therapeutic Advances
A CME/CE-certified Breakfast Symposium in conjunction with the National Lipid Association’s 2013 Annual Scientific Sessions

Registration Statement

By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


View Agenda  Red Rock HotelLas Vegas, NV Saturday
Jun 1, 2013 7:00 AM


  Venue City State Date  
View Agenda  Red Rock Hotel Las Vegas NV Saturday, June 1, 2013 7:00AM To register scroll down.

Program Description

Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder associated with inordinately high blood levels of LDL-C. HoFH and uncontrolled severe hypercholesterolemia can lead to premature atherosclerosis and early death from major adverse cardiovascular events. Because of the severe adverse clinical impact of HoFH/severe hypercholesterolemia, this lifelong disease mandates early intervention to avert devastating cardiovascular complications. However, it remains greatly under-diagnosed and under-treated, and affected patients continue to bear an unacceptably high CVD risk burden.

This hard reality could be due, in part, to the fact that traditional treatments are inadequate in normalizing LDL-C and reducing CVD risk. However, 2 new drugs have recently been approved by the FDA for adjunctive treatment of HoFH. Although working through different mechanisms of action, they ultimately target the inhibition of apolipoprotein B-100 to prevent release of LDL-C into the circulation; thereby, achieving robust reduction of circulating LDL-C levels. These recent advances warrant education on the adoption of these novel treatments to reach appropriate targeted goals for HoFH patients.


Daniel J. Rader, MD - Chair
Chief, Division of Translational Medicine and Human Genetics
Edward S. Cooper, MD/Norman Roosevelt and Elizabeth Meriwether McLure
Professor of Medicine and Pharmacology
Director, Preventive Cardiovascular Medicine and Lipid Clinic
Director, Clinical and Translational Research Center
Associate Director, Institute for Translational Medicine and Therapeutics
Director, Cardiovascular Metabolism Unit
Institute for Diabetes, Obesity, and Metabolism
Perelman School of Medicine University of Pennsylvania
Philadelphia, PA

Eliot A. Brinton, MD, FAHA, FNLA
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, UT

Peter P. Toth, MD, PhD
Director of Preventative Cardiology
CGH Medical Center,
Sterling, IL
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI

Target Audience

The primary audiences for this educational initiative include cardiologists, internists, lipidologists, pharmacists, registered nurses, registered dietitians, and other healthcare professionals specializing in cardiology and endocrinology.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Adopt screening strategies, including youth and cascade screening, for prompt identification of HoFH/severe hypercholesterolemia and early implementation of treatment
  • Implement intense drug combination LDL-lowering strategies for lifelong management of HoFH/severe hypercholesterolemia (consider referral to lipidologist)
  • Discuss the latest clinical data on novel therapies for HoFH/severe hypercholesterolemia, including efficacy and safety profiles, when determining management plans for optimal outcomes
  • For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families.


Registration and Breakfast:   7:00am – 7:30am
CME/CE Program:   7:30am – 8:30am
7:00 – 7:30am   Registration and Breakfast
7:30 – 7:35am   Introduction and Welcome – Dr. Rader
7:35 – 7:50am   Early screening and prompt treatment initiation – Dr. Brinton
7:50 – 8:05am   Traditional intense drug combination treatments – Dr. Toth
8:05 – 8:20am   Newly approved next generation therapies – Dr. Rader
8:20 – 8:30am   Summary and Concluding Remarks – Dr. Rader


CME credit provided by the National Lipid Association

The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this live activity for a maximum of 1 AMA PRA Category I credit(s)™. Physicians should claim only credit commensurate with the extent of their participation the activity.

Physician Assistants
NCCPA accepts AMA PRA Category I credit(s)™ from organizations accredited by ACCME.

CE credit provided by Postgraduate Institute for Medicine


Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Universal Activity Number- 0809-9999-13-291-L01-P
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour (.1 CEUs) of the Accreditation Council for Pharmacy Education.

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program.

This education activity for .9 contact hours is provided by Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nursing Credentialing Center's Commission on Accreditation.

Criteria for Success

Statements of credit will be awarded based on the participant's attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.

Disclosure Statement

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

Commercial Support

Full notification of commercial support will be provided in the activity syllabus.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form.

There are no fees associated with this program.


Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.). Please email at least 5 days prior to the program.


This activity is Co-provided/Co-sponsored by the National Lipid Association.
This activity is Co-provided/Co-sponsored by Rockpointe.
This activity is Co-provided/Co-sponsored by Postgraduate Institute for Medicine.

Supported By

Supported by an educational grant from Aegerion Pharmaceuticals, Inc.

Registration Statement

By clicking the Registration Button below you are agreeing that you have read and understood the CME/CE Statements above.

Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.


View Agenda  Red Rock HotelLas Vegas, NV Saturday
Jun 1, 2013 7:00 AM